Trials / Unknown
UnknownNCT04324879
A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)
A Open-label, Single-arm, Multicenter Phase Ⅱ Clinical Trial of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy of TQ-B3525 in patients with relapsed / refractory follicular lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-B3525 | TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle. |
Timeline
- Start date
- 2020-05-20
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2020-03-27
- Last updated
- 2020-07-01
Locations
41 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04324879. Inclusion in this directory is not an endorsement.